Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin + empagliflozin tablets for type 2 diabetes in routine clinical practice
ChiCTR2300074612Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of metformin and empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Blood glucose clinical control up to standard rate. Started Aug 2023; status: recruiting.
02
Drugs
metforminempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2300074612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074612.